The effect of oxfendazole terminated infections with Haemonchus contortus on the development of immunity in sheep.
The relative contribution of third (L3), fourth (L4) or adult stages of Haemonchus contortus to the development of immunity was evaluated in three groups of sheep subjected to infections terminated by oxfendazole treatments at the L3, L4 or adult stage. A control group did not receive immunising infections. All the groups were challenged with 5000 L3, to evaluate the protection provided by the different protocols. All sheep were necropsied at the end of the experiment to count the abomasal worm burdens. A marked reduction in egg counts after challenge infection was only observed in sheep in which the infection was terminated in the adult stage (Group 4). A significant reduction in worm burden was also observed in Group 4. The immunising infections and/or the challenge infection resulted in moderately elevated IgG antibody levels against L3, L4 and adult somatic antigens in all the groups. In contrast, a strong IgG response against H. contortus excretory/secretory (ES) antigens was observed in the groups in which the immunising infection was terminated in the L4 and the adult stage. An elevated lymphocyte proliferation response against Haemonchus ES antigens was found only in the group that had their immunising infection terminated at the adult stage. The combined data suggest that exposure to and elicited immunological responses to ES antigens are important for the development of immunity against H. contortus.
Schallig
H D
HD
Department of Parasitology and Tropical Veterinary Medicine, Utrecht University, Institute of Infectious Diseases and Immunology, The Netherlands. rita.henk@consunet.nl
van der Aar
W M
WM
Boersema
J H
JH
Cornelissen
A W
AW
D000018:Abomasum / Q000469:parasitology; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000096:biosynthesis / Q000097:blood; D000947:Antigens, Helminth / Q000276:immunology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005243:Feces / Q000469:parasitology; D006188:Haemonchiasis / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D006189:Haemonchus / Q000187:drug effects / Q000254:growth & development / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D007814:Larva / Q000276:immunology; D008213:Lymphocyte Activation; D010270:Parasite Egg Count / Q000662:veterinary; D012588:Scintillation Counting / Q000662:veterinary; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology
D000871:Anthelmintics; D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D001562:Benzimidazoles; D007074:Immunoglobulin G; C011030:oxfendazole